KSQ Therapeutics Appoints Richard Moscicki, MD, to Board of Directors
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep 25, 2018--KSQ Therapeutics today announced the appointment of Richard A. Moscicki, MD, to the company’s Board of Directors. Dr. Moscicki brings more than 25 years of leadership experience in translational medicine, clinical development, regulatory affairs and medical affairs in the pharmaceutical industry. His background includes serving in leadership roles in the U.S. Food and Drug Administration’s (FDA’s) Center for Drug Evaluation and Research (CDER) and in medical affairs and clinical development at Genzyme and Sanofi-Genzyme. Dr. Moscicki will join as an independent director of KSQ Therapeutics.
“Rich brings extensive industry and regulatory knowledge for advancing innovative medicines through the drug development process, which will be a valuable asset to KSQ as we advance our pipeline of immunotherapies and targeted therapies in oncology,” said David Meeker, MD, Chief Executive Officer of KSQ. “We are delighted to welcome such an experienced and well-respected industry leader as Rich to the KSQ board, and we look forward to working together.”
“I am excited to become part of the pioneering drug development approach at KSQ, which has the potential to improve the quality of drug targets and, therefore, offer the potential to shorten drug development timelines and increase the pace of bringing meaningful medicines to patients,” said Dr. Moscicki. “I look forward to working with the KSQ team on the most near-term opportunities for the company to advance promising oncology therapies through clinical development and to cancer patients, as well as the broader opportunities ahead to apply CRISPRomics in other disease areas.”
Dr. Moscicki is currently the Executive Vice President for Science and Regulatory Advocacy and the Chief Medical Officer at Pharmaceutical Research and Manufacturers of America (PhRMA). From 2013 to 2017, prior to joining PhRMA, he served as the Deputy Center Director for Science Operations for the U.S. Food and Drug Administration’s (FDA’s) Center for Drug Evaluation and Research (CDER). Dr. Moscicki was senior vice president and head of Clinical Development at Sanofi-Genzyme from 2011-2013. He was Chief Medical Officer at Genzyme Corporation from 1992 to 2011, where he was responsible for worldwide global regulatory and pharmacovigilance, as well as all aspects of clinical research and medical affairs. Dr. Moscicki is board certified in internal medicine, diagnostic and laboratory immunology, and allergy and immunology. He completed his residency in internal medicine, followed by a fellowship at Massachusetts General Hospital in clinical immunology and immunopathology. He remained on staff at MGH and on the faculty of Harvard Medical School from 1979 until 2013. Dr. Moscicki received his medical degree from Northwestern University Medical School.
About KSQ Therapeutics
KSQ Therapeutics is using CRISPR technology within a powerful drug discovery engine to enable high confidence drug development. The company is advancing a pipeline of tumor- and immune-focused drug candidates for the treatment of cancer, across multiple drug modalities including targeted therapies, adoptive cell therapies and immuno-therapies. KSQ’s proprietary CRISPRomics™ drug discovery engine enables genome-scale, in vivo validated, unbiased drug discovery across broad therapeutic areas. KSQ was founded by thought leaders in the field of functional genomics and pioneers of CRISPR screening technologies, and the company is located in Cambridge, Massachusetts. For more information, please visit the company’s website at www.ksqtx.com.
View source version on businesswire.com:https://www.businesswire.com/news/home/20180925005348/en/
CONTACT: The Yates Network
Kathryn Morris, 914-204-6412
KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY ONCOLOGY PHARMACEUTICAL
SOURCE: KSQ Therapeutics
Copyright Business Wire 2018.
PUB: 09/25/2018 08:00 AM/DISC: 09/25/2018 08:01 AM